Charles A. Deignan
2015
In 2015, Charles A. Deignan earned a total compensation of $497.1K as Chief Financial Officer at Clearside Biomedical.
Compensation breakdown
| Bonus | $8,750 |
|---|---|
| Non-Equity Incentive Plan | $61,250 |
| Option Awards | $177,100 |
| Salary | $250,000 |
| Total | $497,100 |
Deignan received $250K in salary, accounting for 50% of the total pay in 2015.
Deignan also received $8.8K in bonus, $61.3K in non-equity incentive plan and $177.1K in option awards.
Rankings
In 2015, Charles A. Deignan's compensation ranked 10,837th out of 13,638 executives tracked by ExecPay. In other words, Deignan earned more than 20.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,837 out of 13,638 | 21st |
Division Manufacturing | 4,137 out of 5,190 | 20th |
Major group Chemicals And Allied Products | 1,516 out of 1,854 | 18th |
Industry group Drugs | 1,250 out of 1,528 | 18th |
Industry Pharmaceutical Preparations | 976 out of 1,182 | 17th |
Source: SEC filing on April 28, 2017.
Deignan's colleagues
We found two more compensation records of executives who worked with Charles A. Deignan at Clearside Biomedical in 2015.
News
Clearside Biomedical CEO George Lasezkay's 2023 pay stays at $1.5M
April 26, 2024
Clearside Biomedical CEO George Lasezkay's 2022 pay falls 35% to $1.5M
April 28, 2023
Clearside Biomedical President and Chief Executive Office George Lasezkay's 2021 pay jumps 71% to $2.3M
April 29, 2022
Clearside Biomedical Chief Commercial Officer Brion Raymond receives $954K in 2018
April 26, 2019